Subscribe to Search results

Jackie Britton described her experience at two hospitals. At one hospital "you fought for your six-monthly scans, which could take eight months, and then it was a wait to see your consultant" and contrasted this with her later experience: "with King's [College Hospital] you have the scan in the morning, you see the clinic in the afternoon."

Published on:

Michelle Tolley described the differences in care at two hospitals:"you have your scan, you might wait three or four weeks for a letter and then you see your hepatologist, if you're lucky, and then you get sent off for bloods ... not like at King's [College Hospital], where you have your scan in the morning, your bloods, and then you see the person in the afternoon. That's all done and dusted."

Published on:

A paper containing an economic analaysis of screening blood donations against Hepatitis C referred to a research programme a research programme had begun to evaluate the use of interferon therapy in non-A non-B Hepatitis.

Published on:

Letter from Dr Dr K Bywater to Dr Kenneth Calman stated that although Interferon treatment was licensed for use in January 1995 it had been used in specialist centres in the UK and around the world for the previous 5 years.

Published on:

The effectiveness of interferon against Hepatitis C was demonstrated for the first time by Dr Jay Hoofnagle.

Published on:

Combination therapy was the mainstay of treatment from 2000, with interferon being part of the combination until around 2014.

Published on:

Interferon alpha monotherapy was the only treatment licensed for use in treatment of Hepatitis C in the UK.

Published on:

Interferon was used in some specialist centres (on a named person basis) for some five years prior to licensing.

Published on:

Direct-acting antivirals became available for treatment for Hepatitis C.

Published on:

Pegylated interferon was used as monotherapy in the UK from June 2002 and was deemed to provide better results.

Published on:

A preliminary report on the "SNBTS Evaluation of the Ortho HCV Antibody ELISA Test System" looked at transfusion recipients, and found that 1 in 33 multi-transfused patients screened positive (3%). 92 of 146 people with haemophilia from the West of Scotland whose samples were tested were shown to be repeatedly reactive for anti-HCV (63%).

Published on:

Dr Metters reported to the meeting that France, Belgium and Luxembourg had all commenced mandatory screening, while Italy had introduced optional screening.

Published on:

Arrangements for implementing anti-HCV screening were discussed in detail by the Advisory Committee on Transfusion Transmitted Diseases.

Published on:

Dr Contreras wrote that, "We are extremely busy with our Business Plans and contracts as well as dealing with the extra workload incurred as a result of the Gulf War and we cannot give anti-HCV screening the priority required by the Department of Health."

Published on:

A letter from S McDougall to Dr Gunson noted that the commencement of routine anti-HCV testing at the Cambridge RTC was unlikely to start before 1 October 1991.

Published on:

A letter from Dr Fereydoun Ala to Dr Gunson noted that routine testing for HCV in the West Midlands RTC could begin by April 1991.

Published on:

A letter from Professor Cash to Dr Gunson noted that a May/June date might be anticipated to commence anti-HCV testing in Scotland.

Published on:

A letter from Dr Martlew to Dr Gunson noted that they would prefer to delay the implementation of anti-HCV testing at the Liverpool RTC to 1 August 1991.

Published on:

A letter from Dr Fraser to Dr Gunson stated that 1 July 1991 would be the most appropriate date to start anti-HCV testing at the Bristol RTC.

Published on:

A letter from Jean Harrison to Dr Gunson stated that the earliest the Brentwood RTC could start anti-HCV testing would be 15 April 1991, but the preferred start date would be 1 May 1991 or 1 June 1991.

Published on: